Roundup® Cancer Litigation | Non-Hodgkin Lymphoma Claims
Billion-Dollar Settlements Are Here. Don’t Let Your Claim Be Left Behind.
For decades, Monsanto and its parent company, Bayer, marketed Roundup® as “safer than table salt” while internal documents suggested they knew of its link to cancer. At Nigh Goldenberg Raso & Vaughn, we take on the world’s most powerful corporations. We are currently helping victims of Roundup exposure navigate the historic $7.25 Billion Settlement announced in February 2026.
[Button: Check My Settlement Eligibility] [Button: Call Our Toxic Tort Team]
⚠️ CRITICAL UPDATE: The $7.25 Billion “Closure” Deal
On February 17, 2026, Bayer proposed a massive $7.25 billion nationwide settlement to resolve current and future Non-Hodgkin Lymphoma (NHL) claims. But there is a catch. The deal is designed to “contain” litigation over the next 20 years. To ensure you receive the maximum tiered payout—which can reach up to $165,000 to $198,000 for aggressive cases—you need a law firm that knows how to prove the severity of your exposure and diagnosis.
The Four Pillars of Roundup® Negligence
We hold Bayer/Monsanto accountable for the science they ignored and the warnings they never gave.
1. The “Ghostwriting” Scandal
Internal emails revealed that Monsanto employees drafted scientific papers and then paid “independent” scientists to sign their names to them. These “Monsanto Papers” show juries that the company manipulated the science to keep Roundup on the shelves.
2. Failure to Warn (The Supreme Court Battle)
While Bayer argues that EPA approval shields them from lawsuits, we fight for your right to be warned. We are closely monitoring the U.S. Supreme Court’s 2026 review of the Durnell case, which will determine if federal law can strip away your right to sue under state law. We act now to lock in your claim before legal landscapes shift.
3. Occupational vs. Residential Exposure
Whether you were a commercial farmer, a landscaper, or a homeowner who used Roundup in your backyard, your exposure matters. The Roundup settlement utilizes a “tiered-grid” to categorize your usage and maximize your compensation under the new settlement framework.
4. Non-Hodgkin Lymphoma (NHL) Subtypes
Roundup is specifically linked to NHL and its subtypes, including B-cell Lymphoma, T-cell Lymphoma, and Chronic Lymphocytic Leukemia (CLL). We hire top oncologists to link your specific pathology to your history of glyphosate exposure.
The Evidence: Proving Toxic Exposure
To win a Roundup case, you must prove both the exposure and the injury. NGRV utilizes:
- Purchase Records & Invoices: We try to hunt down decades-old records from hardware stores, farm cooperatives, and landscaping contracts.
- Oncology Forensics: We analyze your biopsy and pathology reports related to NHL.
- Expert Testimony: We work with toxicologists and epidemiologists who can explain to a jury exactly how glyphosate disrupts human cell biology.
The NGRV Advantage: Experience in Mass Torts
- National Leadership: Our attorneys, including Daniel Nigh, hold leadership roles in some of the largest mass torts in the country. We don’t just follow the litigation; we lead it.
- Settlement Maximization: We don’t accept the first “Quick-Pay” offer. We fight for the “Extraordinary Injury” enhancements that can significantly increase your payout.
- Contingency-Based Justice: You’ve already paid enough in medical bills. We front all litigation costs. We only get paid if you receive a settlement or verdict.
FAQ: Roundup® & Your Rights in 2026
Who is eligible for the new 2026 settlement?
Generally, anyone exposed to Roundup who was diagnosed with Non-Hodgkin Lymphoma (NHL) before February 17, 2026, or those who may be diagnosed within the next 16 years.
What if the Supreme Court rules in favor of Bayer?
The current $7.25 billion settlement is designed to provide “certainty” regardless of the Supreme Court’s decision.
I used Roundup years ago but was just diagnosed. Can I still sue?
Yes. The latency period for NHL can be decades. The new settlement specifically includes provisions for “future claimants” diagnosed after years of prior exposure.
